CLAIMS

1. Use of acetyl-leucine, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing a migraine, or one or more symptoms associated therewith.

2. The use according to claim 1, wherein the acetyl-leucine or pharmaceutically acceptable salt thereof reduces the frequency of, alleviates or eliminates one or more migraine symptoms selected from headache, tiredness, aura, nausea, vomiting, sensitivity to light, sensitivity to sound, sensitivity to smell, sweating, poor concentration, feeling hot, feeling cold, abdominal pain and diarrhoea.

3. The use according to claim 1 or claim 2, wherein the acetyl-leucine or pharmaceutically acceptable salt thereof reduces, alleviates or eliminates migraine headaches.

4. The use according to claim 1 or claim 2, wherein the acetyl-leucine or pharmaceutically acceptable salt thereof is for treating or preventing an aura.

5. The use according to claim 1 or claim 2, wherein the acetyl-leucine or pharmaceutically acceptable salt thereof is for treating or preventing an aura associated with a migraine headache.

6. The use according to claim 1 or claim 2, wherein the acetyl-leucine or pharmaceutically acceptable salt thereof is for treating or preventing an aura without a migraine headache.

7. The use according to any one of claims 4-6, wherein the acetyl-leucine or pharmaceutically acceptable salt thereof reduces the frequency of, alleviates or eliminates one or more symptoms selected from visual problems or visual disturbances, numbness or tingling, dizziness, balance problems, motor problems, speech difficulties and loss of consciousness.

8. The use according to claim 1 or claim 2, wherein the acetyl-leucine or pharmaceutically acceptable salt thereof is for treating or preventing a migraine that is not associated with an aura.

9. The use according to claim 1 or claim 2, for treating or preventing a migraine associated with an aura.

10. The use according to claim 1 or claim 2, for treating or preventing a hemiplegic migraine, a sporadic hemiplegic migraine, a vestibular migraine, a basilar-type migraine or a retinal migraine.

11. The use according to claim 1 or claim 2, wherein the acetyl-leucine or pharmaceutically acceptable salt thereof is for

a. treating or preventing a migraine that is not a vestibular migraine;

b. treating or preventing a migraine that is not a vestibular migraine associated with symptoms of vertigo;

c. treating or preventing a migraine that is not associated with vertigo or symptoms of vertigo; and/or

d. treating or preventing a migraine that is not associated with acute vertigo or vertigo due to an acute peripheral vestibular lesion.

12. The use according to claim 1 or claim 2, for treating or preventing chronic migraine.

13. The use according to claim 1 or claim 2, for treating or preventing episodic migraine.

14. The use according to claim 1 or claim 2, for treating or preventing one or more prodromal symptoms associated with a migraine.

15. The use according to claim 1 or claim 2, for treating or preventing pain associated with a migraine.

16. The use according to claim 1 or claim 2, for treating or preventing one or more postdromal symptoms associated with a migraine.

17. The use according to any preceding claim, wherein the acetyl-leucine is in racemic form.

18. The use according to any one of claims 1 to 16, wherein the acetyl-leucine is in an enantiomeric excess of the L-enantiomer or in an enantiomeric excess of the D-enantiomer.

19. The use according to any preceding claim, wherein the acetyl-leucine, or pharmaceutically acceptable salt thereof, is to be administered once a day or twice a day.

20. The use according to any one of claims 1 to 18, wherein the acetyl-leucine, or pharmaceutically acceptable salt thereof, is to be administered three times a day.

21. The use according to any preceding claim, wherein the acetyl-leucine, or pharmaceutically acceptable salt thereof, is to be administered for a treatment duration of two weeks or more.

22. The use according to any preceding claim, wherein the acetyl-leucine, or pharmaceutically acceptable salt thereof, is to be administered in a dose of from about 500 mg to about 15 g per day.

23. The use according to any preceding claim, wherein the acetyl-leucine, or pharmaceutically acceptable salt thereof, is to be administered in a dose of from about 1500 mg to about 6000 mg per day.

24. The use according to any preceding claim, wherein the acetyl-leucine, or pharmaceutically acceptable salt thereof, is to be administered in a dose of from about 2500 mg to about 5500 mg per day.

25. The use according to any preceding claim, wherein the acetyl-leucine, or pharmaceutically acceptable salt thereof, is to be administered in a total dose of about 3000 mg per day.

26. The use according to claim 25, wherein the acetyl-leucine, or pharmaceutically acceptable salt thereof, is to be administered in a dose of 1000 mg three times a day, preferably two 500 mg tablets for administration three times a day.

27. The use according to any one of claims 1 to 24, wherein the acetyl-leucine, or pharmaceutically acceptable salt thereof, is to be administered in a total dose of about 4500 mg per day.

28. The use according to claim 27, wherein the acetyl-leucine, or pharmaceutically acceptable salt thereof, is to be administered in a dose of 1500 mg three times a day, preferably three 500 mg tablets for administration three times a day.

29. The use according to any one of claims 1 to 24, wherein the acetyl-leucine, or pharmaceutically acceptable salt thereof, is to be administered in a total dose of about 5000 mg per day.

30. The use according to claim 29, wherein the acetyl-leucine, or pharmaceutically acceptable salt thereof, is to be administered in one dose of four 500 mg tablets, and two doses of three 500 mg tablets.

31. The use according to any one of claims 1 to 24, wherein the acetyl-leucine, or pharmaceutically acceptable salt thereof, is to be administered in a total dose of about 5500 mg per day.

32. The use according to claim 31, wherein the acetyl-leucine, or pharmaceutically acceptable salt thereof, is to be administered in two doses of four 500 mg tablets, and one dose of three 500 mg tablets